Liquid biopsy - the future of cancer screening

The Cancer Diagnostic Technology Summit virtual conference takes place from May 11th to May 14th.

Liquid biopsy image

Moving advanced healthcare technology from the laboratory to the clinic necessarily requires the support of a commercial organisation to effect the transition. 

For that reason the Cancer Diagnostic Technology Summit includes presentations by both academic and industry speakers.

LIquid biopsy, in which a sample of blood or other fluid, is examined for cancer biomarkers, offers most hope for a low cost, accessible cancer screening tool.  The technology, which is developing rapidly, can provide multi-test platforms to identify several cancer types in a single sample.

Among Speakers on Liquid Biopsy at CDT21 on 11th May are:

  • Sara Hiom, GRAIL Europe: Multi-cancer early detection

  • Dr, Heather Parsons MD, Dana Farber Cancer Institute: Detecting minimal residual disease in breast cancer

  • Dr. Sylvain Ladame, Imperial College: Detecting  nucleic acid biomarkers at the point of care

  • Dr. Rui Campos, University of Antwerp: Electrochemiluminescent assay for prostate cancer

The conference also includes sessions on: VOC Biomarkers; The Pathway to Early Diagnosis; Cell Separation; Advanced Technology in Cancer Detection; Imaging: AI in Clinical Judgement.

Image removed.

Image removed.



Looking for something specific?